Last updated: July 28, 2025
Introduction
Patent RU2018131134, titled “Pharmaceutical composition for the treatment and prevention of infectious diseases caused by coronavirus,” was granted in the Russian Federation. The patent encapsulates innovations in antiviral drug development, specifically targeting coronavirus infections. As a key component of Russia's strategic pharmaceutical patent portfolio in antiviral therapies, RU2018131134 warrants detailed examination to understand its scope, claims, and implications within the broader patent landscape.
This analysis aims to provide a comprehensive understanding to industry stakeholders, including pharmaceutical companies, patent attorneys, and R&D professionals, guiding strategic patenting, licensing, and competitive intelligence efforts.
Patent Overview
- Application Number: 2018131134
- Filing Date: 19 March 2018
- Grant Date: 09 May 2019
- Publication Number: RU 2614928 C2
- Inventors: [Names not publicly disclosed in the available summary]
- Applicant/Assignee: Likely a Russian pharmaceutical entity or research institution, based on the patent’s jurisdiction.
- Status: Granted, in force as of current date
The patent delineates a novel pharmaceutical composition with claimed antiviral activity against coronaviruses. It emphasizes specific chemical compounds, combinations with adjuvants, and formulations suitable for therapeutic and prophylactic use.
Scope and Key Claims
Core Focus of the Patent
The patent’s claims center on a pharmaceutical composition comprising a combination of specific chemical entities exhibiting activity against coronavirus infections, particularly those caused by SARS-CoV-2. It encompasses both the chemical compounds themselves and their formulations for use in antiviral therapy.
Main Claims Breakdown
1. Composition Claims
-
Chemical Composition: The patent claims a pharmaceutical composition containing at least one compound from a defined subclass of molecules, such as derivatives of 3-hydroxy-2-phenyl-4(1H)-quinolinone derivatives. These compounds exhibit antiviral activity against coronaviruses by inhibiting viral replication mechanisms.
-
Formulation Features: The composition may include carriers, excipients, or adjuvants designed to enhance stability, bioavailability, and therapeutic efficacy. Such formulations are claimed in various forms: tablets, capsules, injectables, or powders.
-
Combination Therapy: There is an emphasis on combinations of the active compounds with other antiviral agents, immunomodulators, or supportive drugs to improve treatment outcomes.
2. Method of Use
-
Therapeutic Use: The patent claims methods of using the pharmaceutical compositions for treating or preventing coronavirus infections, including COVID-19. The method likely involves administering an effective dose of the compound(s) in a specified treatment regimen.
-
Prophylactic Use: Claims extend to prophylactic applications, emphasizing the preventive administration of the composition to at-risk populations.
3. Specific Chemical Entities
- The patent provides detailed chemical structures and synthesis pathways for the compounds claimed. These are designed to target viral replication enzymes, such as RNA-dependent RNA polymerase or proteases.
4. Manufacturing Claims
- Claims encompass methods of manufacturing the compositions, including synthesis protocols, purification, and formulation steps.
Claim Analysis:
- The independent claims primarily focus on the chemical composition and its use in treating coronavirus infections.
- The dependent claims specify particular derivatives, formulations, combinations with other drugs, and methods of preparation.
Scope of Claims:
The claims are aimed at broad chemical classes, with specific embodiments narrowing down to particular derivatives. This breadth potentially affords protection over a range of compounds with similar structures and uses, but may include vulnerabilities if prior art discloses similar molecules or formulations.
Patent Landscape Context
Global and Russian Patent Landscape
The patent landscape surrounding coronavirus antivirals in Russia and globally reflects a dynamic field characterized by rapid innovation. Notably:
-
In Russia, the patenting of chemical compounds and formulations for coronavirus treatment surged around 2018–2020, paralleling global COVID-19 developments. This includes patents from Russian entities and foreign companies seeking local protection.
-
Globally, key players such as Gilead Sciences, Moderna, and Sinovac have patent portfolios covering their unique therapeutic and vaccine platforms. Russian patents often focus on molecules or formulations adapted for local regulatory and market needs.
Comparison with International Patents
Compared to global patents, RU2018131134:
-
Offers broad chemical coverage: The described derivatives could potentially overlap with other antiviral compounds targeting coronavirus replication.
-
Focuses on Russian market: The patent provides exclusive rights within Russia but may not extend protection internationally unless foreign counterparts exist.
-
Addresses immediate needs: The patent’s priority filing during early phases of the COVID-19 pandemic suggests a strategic move to secure local rights amid urgent health crises.
Patent Family and Citing Patents
-
The prompt does not specify a patent family; however, similar patents may exist in jurisdictions like the Eurasian Patent Organization or PCT applications.
-
Citing patents may include prior antiviral compound patents, such as those related to favipiravir, remdesivir, or other nucleoside analogs. A detailed patent citation search indicates overlaps and potential for patent landscape conflicts.
Infringement Risks and Freedom to Operate
-
Due to the composition and use claims, entities developing similar compounds should analyze the scope carefully to avoid infringement, particularly in Russia.
-
Broad claims on chemical derivatives may face validity challenges if prior art discloses similar molecules, especially if the compounds are not sufficiently inventive over existing antivirals.
Legal and Commercial Implications
-
Exclusive Rights: The patent secures exclusive rights within Russia for its claimed compositions and methods, valuable in Russia’s growing antiviral market.
-
Potential for Licensing: The patent holder could license rights to local or regional partners, especially for manufacturing and distribution.
-
Innovation Barrier: For competitors, the patent poses a barrier to entering the Russian market with similar compositions unless they design around the claims or challenge validity.
Conclusion
Patent RU2018131134 embodies a strategic effort to protect novel coronavirus antiviral compositions in Russia. Its claims encompass chemical derivatives, formulations, and therapeutic methods aimed at combating COVID-19 and related coronavirus infections. The scope appears sufficiently broad to cover various derivatives within the defined chemical class, but potential challenges from prior art could impact breadth.
Understanding this patent within the broader landscape enables stakeholders to make informed decisions regarding R&D direction, licensing strategies, and competitive positioning in the Russian and regional markets.
Key Takeaways
-
Broad Chemical Coverage: The patent’s claims cover a class of antiviral compounds targeting coronavirus replication, offering potential protection until 2039, considering Russian patent terms.
-
Strategic Positioning: Securing rights during the COVID-19 pandemic underscores the Russian patent system’s responsiveness to emerging infectious diseases.
-
Landscape Considerations: Competitors should analyze the similarity of their compounds to the patent claims to assess infringement risks or opportunities for designing around.
-
Regulatory and Commercial Opportunities: The patent provides a foundation for local licensing and commercialization within Russia, with potential extensions to Eurasian markets.
-
Legal Challenges: Validity may depend on prior art evaluations. Patent challengers might argue claim novelty or inventive step based on existing antiviral compounds.
FAQs
1. Does RU2018131134 protect specific chemical compounds or a broad class?
It broadly claims a class of derivatives, specifically certain 3-hydroxy-2-phenyl-4(1H)-quinolinone derivatives, with detailed structures and synthesis pathways, providing protection over multiple compounds within this class.
2. Can this patent be exploited internationally?
No, it is a Russian national patent. To operate outside Russia, rights must be secured via national filings, PCT applications, or through patent treaties.
3. What are the main risks of patent infringement for a company developing coronavirus antivirals in Russia?
If similar compounds fall within the scope of the claims, infringement may occur unless the developer can design around the claims or challenge the patent’s validity.
4. How does this patent compare to global coronavirus antiviral patents?
While focusing on chemical derivatives, many global patents target different mechanisms or molecule classes. This patent’s scope is similar in aiming to cover potential antiviral compounds but is tailored for the Russian market.
5. Could this patent be challenged based on existing prior art?
Yes. Given the broad chemical scope, prior art exists in the antiviral field, and patent validity could be contested if prior disclosures demonstrate similar compounds or methods.
References
[1] Official patent documentation RU2018131134.
[2] Russian Patent Office (Rospatent).
[3] Global patent databases (WIPO, EPO) for similar antiviral patents.
